Two Centers, One Mission
The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will 1) design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD), and 2) initiate early stage drug discovery campaigns against the enabled targets. Central to this initiative is the open-access, rapid dissemination of data, methods, and computational and experimental tools generated by the Centers to all qualified researchers for their use in advancing AD drug discovery and AD disease biology.
External Advisory Board:
Kelly Bales, Voyager Therapeutics Inc.
David Collier, Eli Lilly
Gabriela Chiosis, Sloan Kettering Institute
Rebecca Edelmayer, Alzheimer’s Association
Nilufer Ertekin-Taner, Mayo Clinic
Mark Gurney, Tetra Therapeutics
David Holtzman, Washington University School of Medicine, St. Louis
Philip De Jager, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University
Kalpana Merchant, Adjunct Professor of Neurology at Northwestern University Feinberg School of Medicine
Eric Siemers, Siemers Integration LLC
Reisa Sperling, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School
Linda Van Eldik, Sanders-Brown Center on Aging, University of Kentucky